Agomelatine in the Treatment of Major Depressive Disorder
- 1 June 2010
- journal article
- review article
- Published by Springer Nature in CNS Drugs
- Vol. 24 (6) , 479-499
Abstract
To demonstrate the clinical effectiveness of an antidepressant drug requires evidence beyond short- and long-term efficacy, including a favourable adverse-effect profile and sustained treatment adherence. Under these conditions, patients should experience enhanced social and functional outcomes. The novel antidepressant agomelatine, a melatonergic MT1/MT2 receptor agonist with serotonin 5-HT2C receptor antagonist activity, displays antidepressant efficacy with a favourable adverse-effect profile that is associated with good patient adherence. Specifically, agomelatine has demonstrated significant short-term (6–8 weeks) and sustained (6 months) antidepressant efficacy relative to placebo, as well as evidence of relapse prevention (up to 10 months). In head-to-head comparative studies with venlafaxine and sertraline, there was evidence of early (at 1–2 weeks) and sustained (at 6 months) advantages for agomelatine. In addition to evidence of early efficacy, agomelatine also restored disturbed sleep-wake patterns early in treatment. There was no evidence of antidepressant-induced sexual dysfunction, weight gain or discontinuation-emergent symptoms. Agomelatine has demonstrated a range of properties that suggest it could offer advantages over current treatments for major depressive disorder, although further comparative trials are still required, as is evidence from real-world clinical practice.Keywords
This publication has 87 references indexed in Scilit:
- Efficacy of the Novel Antidepressant Agomelatine on the Circadian Rest-Activity Cycle and Depressive and Anxiety Symptoms in Patients With Major Depressive DisorderThe Journal of Clinical Psychiatry, 2010
- Selective Publication of Antidepressant Trials and Its Influence on Apparent EfficacyNew England Journal of Medicine, 2008
- Explaining Patients' Beliefs About the Necessity and Harmfulness of AntidepressantsThe Annals of Family Medicine, 2008
- Adherence to Depression Treatment in Older AdultsDrugs & Aging, 2008
- Adherence to Antidepressant Treatment Among Privately Insured Patients Diagnosed With DepressionMedical Care, 2007
- Estimating the Prevalence and Impact of Antidepressant-Induced Sexual Dysfunction in 2 European CountriesThe Journal of Clinical Psychiatry, 2006
- Impact of Antidepressant Drug Adherence on Comorbid Medication Use and Resource UtilizationArchives of internal medicine (1960), 2005
- Antidepressants and SleepDrugs, 2005
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983
- A New Depression Scale Designed to be Sensitive to ChangeThe British Journal of Psychiatry, 1979